Skip to main content

Advertisement

SpringerLink
Log in

In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the immunotherapeutic potentials for human dendritic cells (DCs) loaded with different HPV16-associated antigens, including HPV16E7 (E) protein, HPV16E7 polypeptide (P), as well as CpG-oligodeoxynucleotide (ODN) 2006 as a promising immune adjuvant for vaccination against cervical carcinoma.

Methods

DCs derived from human peripheral blood and cord blood were isolated and loaded with HPV-derived protein or peptides, in combination with CpG-ODN2006 as a potential adjuvant. The IL-12 level, the allogeneic T cell-stimulatory capacity and the cytotoxicity of cytotoxic T lymphocytes (CTLs) were evaluated in vitro. Furthermore, an immune reconstitution model of human cervical carcinoma in SCID mice was used to assess the anti-tumor effects in vivo. The tumor sizes, the expression of IgG and IFN-γ, and the presence of the human CD3+, CD4+ and CD8+ T cells were measured in the mice inoculated with different DCs.

Results

The antigen-loaded DCs displayed obvious anti-tumor activities in vitro and in vivo, and showed no toxicity to normal cells. The level of IL-12, an important cytokine for immune response, was up-regulated in all mice inoculated with antigen-loaded DCs. Stimulation and activity of CTLs were increased after treatment with antigen-loaded DCs. Significantly, DCs loaded with HPV16E7 polypeptide (P) showed the most distinguished immunotherapeutic activities, and such effect was further enhanced when HPV16E7 polypeptide (P) was used in combination with CpG-ODN2006. Interestingly, the same results were obtained in vivo: the tumor size was decreased, and IgG and IFN-γ levels were increased after the SCID mice were inoculated with the loaded DCs.

Conclusions

HPV16E7 polypeptide combined with the immune adjuvant CpG-ODN2006 could be a suitable HPV16-associated tumor antigen. The research provides a new strategy for generating DCs vaccines for immunotherapy of cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Pagliusi S, Organization WH (2006) Human papillomavirus infection and cervical cancer. World Health Organization Web site http://www.who.int/vaccine_research/diseases/hpv/en/(Slide14)

  2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–1056

    Article  PubMed  Google Scholar 

  3. Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nature Rev Cancer 10:550–560

    Article  CAS  Google Scholar 

  4. Stoler MH (2000) Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 19:16–28

    Article  CAS  PubMed  Google Scholar 

  5. Nonn M, Schinz M, Zumbach K, Pawlita M, Schneider A et al (2003) Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 129:511–520

    Article  CAS  PubMed  Google Scholar 

  6. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A et al (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968–1979

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Rock KL, York IA, Saric T, Goldberg AL (2002) Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80:1–70

    Article  CAS  PubMed  Google Scholar 

  8. Zhou L, Zhu T, Ye X, Yang L, Wang B et al (2009) Long-term protection against human papillomavirus E7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated E7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther 21:109–119

    Article  Google Scholar 

  9. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ et al (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35:946–952

    Article  PubMed  Google Scholar 

  10. Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J et al (1998) Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother 21:399–408

    Article  CAS  PubMed  Google Scholar 

  11. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21–26

    CAS  PubMed  Google Scholar 

  12. Pvd Bruggen, Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Cur opin immunol 18:98–104

    Article  Google Scholar 

  13. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP et al (2001) Bacterial CpG-DNA triggers activation and maturation of human CD11c−, CD123+ dendritic cells. J Immunol 166:5000–5007

    CAS  PubMed  Google Scholar 

  14. Hacker G, Redecke V, Hacker H (2002) Activation of the immune system by bacterial CpG-DNA. Immunology 105:245–251

    Article  CAS  PubMed  Google Scholar 

  15. Mutwiri G, Pontarollo R, Babiuk S, Griebel P, van Drunen Littel-van den Hurk S et al (2003) Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 91: 89–103

    Google Scholar 

  16. Kim TG, Kim CH, Won EH, Bae SM, Ahn WS et al (2004) CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 112:117–125

    Article  CAS  PubMed  Google Scholar 

  17. Krieg AM (2001) From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev 11:181–188

    Article  CAS  PubMed  Google Scholar 

  18. O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235–2246

    Article  PubMed  Google Scholar 

  19. Edmondson JM, Armstrong LS, Martinez AO (1988) A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. J Tissue Culture Methods 11:15–17

    Article  CAS  Google Scholar 

  20. Alli RS, Khar A (2004) Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function. FEBS Lett 559:71–76

    Article  CAS  PubMed  Google Scholar 

  21. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J et al (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Develop Immunol 2010. 10.1155/2010/832454

  22. Ahn W-S, Bae S-M, Kim T-Y, Kim T-G, Lee J-M et al (2003) A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Human Gene Ther 14:1389–1399

    Article  CAS  Google Scholar 

  23. Hemmi H, Kaisho T, Takeda K, Akira S (2003) The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059–3064

    CAS  PubMed  Google Scholar 

  24. Kline JN, Krieg AM (2010) Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapylate. Prog Respir Res 39:95–99

    Article  CAS  Google Scholar 

  25. Ma C, Muranyi M, Chu CH, Zhang J, Chu W-M (2013) Involvement of DNA-PKcs in the IL-6 and IL-12 response to CpG-ODN is mediated by its interaction with TRAF6 in dendritic cells. PLoS ONE 8:e58072

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Kreis N, Sanhaji M, Krämer A, Sommer K, Rödel F et al (2010) Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene 29:5591–5603

    Article  CAS  PubMed  Google Scholar 

  27. Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ et al (2008) Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 99:1034–1039

    Article  CAS  PubMed  Google Scholar 

  28. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ et al (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178–187

    Article  CAS  PubMed  Google Scholar 

  29. Kim T-Y, Myoung H-J, Kim J-H, Moon I-S, Kim T-G et al (2002) Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells involvement of CD4+ and CD8+ T Cells in protection. Cancer Res 62:7234–7240

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Gynecology Department, The Second Hospital of Shandong University, 247 Beiyuan Street, Jinan, Shandong, 250033, China

    Hua Li Wang, Hui Xu, Lin Zhu, Yun Hai Yu & Fan Zhen Hong

  2. Paediatrics Department, The First Hospital of Ningyang County, Taian, Shandong, 271400, China

    Wei Hua Lu

Authors
  1. Hua Li Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Hua Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yun Hai Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fan Zhen Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Li Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, H.L., Xu, H., Lu, W.H. et al. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstet 289, 155–162 (2014). https://doi.org/10.1007/s00404-013-2938-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2938-1

Keywords

Search

Navigation